IN VITRO METHOD FOR PREDICTING THE RESPONSE OF PATIENTS SUFFERING FROM HER2+ BREAST CANCER TO A TREATMENT WITH ANTI-HER2 NEOADJUVANT THERAPY

• Main Authors: MOLINA PINELO, Sonia, GIL TORRALVO, Ana, SALVADOR BOFILL, Francisco Javier, DOMINGUEZ CEJUDO, María Ángeles, GARRIGÓS VACAS, Carmen
• Format: Patent
• Language: English; French
• Published: 08.06.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention refers to an in vitro method for predicting the response of patients suffering from HER2+ breast cancer to a treatment with anti-HER2 neoadjuvant therapy, for deciding or recommending whether to treat patients suffering from HER2+ breast cancer with anti-HER2 neoadjuvant therapy, for classifying HER2+ breast cancer patients into responder or non-responder patients to anti-HER2 neoadjuvant therapy, or for the prognosis of patients suffering from HER2+ breast cancer. La présente invention concerne un procédé in vitro permettant de prédire la réponse des patientes souffrant d'un cancer du sein HER2+ à un traitement par thérapie néoadjuvante anti-HER2, de décider ou de recommander de traiter les patientes souffrant d'un cancer du sein HER2+ par thérapie néoadjuvante anti-HER2, de classer les patientes souffrant d'un cancer du sein HER2+ en patientes répondeuses ou non répondeuses à la thérapie néoadjuvante anti-HER2, ou d'établir le pronostic des patientes souffrant d'un cancer du sein HER2+.